drugset
drugset / Trial / NCT04297124

A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects

NCT04297124 ↗

Phase 1 Completed 8 enrolled Celgene Corporation
NaSingle-groupOpen-labelTreatment

Summary

CC-90009-CP-001 is a Phase 1, single-center, open-label, clinical pharmacology study to measure how much CC 90009 gets into the bloodstream, how much is eliminated in urine and stool, and how long it takes the body to get rid of it. In addition, the safety and tolerability of CC 90009 will be evaluated.

Timeline

Start
2020-03-11
Primary completion
2021-06-04
Completion
2021-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CC-90009 Other / unclassified 0.6 mg Intravenous

Indications

No indication recorded.